Paradigm Biopharmaceuticals Advances Phase 3 Osteoarthritis Trial and Expands Pipeline

An update from Paradigm Biopharmaceuticals ( (AU:PAR) ) is now available.

Paradigm Biopharmaceuticals has commenced its global Phase 3 trial for injectable pentosan polysulfate sodium (iPPS) targeting knee osteoarthritis pain, with patient recruitment underway in Australia and the US. The company has secured strategic funding and expanded its pipeline by acquiring Proteobioactives, enhancing its OA franchise with new treatment options for both human and veterinary markets. These developments position Paradigm to address large, underserved segments of the chronic pain market, potentially improving its industry standing and offering significant benefits to stakeholders.

The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.

More about Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Ltd. is a company operating in the biopharmaceutical industry, focusing on developing treatments for osteoarthritis (OA) and related pain management. The company is expanding its product portfolio to include options for earlier-stage OA and veterinary markets, leveraging its intellectual property in injectable and oral formulations.

Average Trading Volume: 870,654

Technical Sentiment Signal: Buy

Current Market Cap: A$170.9M

For an in-depth examination of PAR stock, go to TipRanks’ Overview page.